Synergy Pharmaceuticals, Inc.

Bausch Health Ireland Limited

Tiziana Life Sciences Plc

Callisto Pharmaceuticals

Okyo Pharma Limited

Kunwar Shailubhai

Gary S Jacob

Stephen Comiskey

Rong Feng

Qiao Zhao

Ruoping Zhang

Juncai Bai

Junfeng Zhou

Jun Jia

Guoqing Zhang

John Foss

Patrick H Griffin

Gregory Nikiforovich

Dennis Riff

Guoquing Zhang

Jun Jian

Rajkumar V Patil

Gray S Jacob

Vaseem Palejwala

The invention provides processes of purifying a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-251 described herein. The processes include a solvent exchange step before a freeze-drying (lyophilization) step.

Ultra-pure agonists of guanylate cyclase C, method of making and using same

The disclosure provides compositions comprising dactinomycin, formulated for delivery by nanoparticle, and methods for treating a myelodysplastic syndrome (MDS) or cancer, for example, NPM1-mutated acute myeloid leukemia (AML), by administration of the compositions of the disclosure.

Dactinomycin compositions and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia

This invention provides a method of colonic cleansing.

Agonists of guanylate cyclase and their uses

This application relates to methods of treating and/or preventing cancer (e.g., non-small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, thyroid carcinoma, colorectal cancer, gastrointestinal stromal tumors, breast cancer, prostate cancer, pancreatic cancer, or thymoma) in patients in need thereof comprising administering to the patient a therapeutically effective amount of a CDK inhibitor (e.g., milciclib) in combination with a therapeutically effective amount of another anticancer drug (e.g., sorafenib, lenvatinib, regorafenib, sunitinib, nivolumab, gemcitabine, and palbociclib).

Formulations of milciclib and therapeutic combinations of the same for use in the treatment of cancer

The invention provides novel guanylate cyclase-C agonist peptides and their use in the treatment of human diseases including gastrointestinal disorders, inflammation or cancer (e.g., a gastrointestinal cancer). The peptides can be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The gastrointestinal disorder may be classified as either irritable bowel syndrome, constipation, or excessive acidity etc. The gastrointestinal disease may be classified as either inflammatory bowel disease or other GI condition, including Crohn's disease and ulcerative colitis, and cancer.

Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders

This invention relates to therapeutic, diagnostic and/or prophylactic formulations and dosages and dosing regimens of anti-CD3 antibodies, as well as to methods for using such formulations and dosages and dosing regimens.

Anti-CD3 antibody formulations

This invention provides composition and methods to prevent, treat or alleviate a symptom of ulcerative colitis comprising administering to a patient dolcanatide.

Formulations and methods for treating ulcerative colitis

This invention provides novel guanylate cyclase C (GC-C) agonists and their therapeutic use. The agonists may be used either alone or in combination with one or more additional agents.

The invention provides processes of preparing a peptide including a GCC agonist sequence selected from the group consisting of SEQ ID NOs: 1-249 described herein.

Growing community of inventors

Audubon, PA, United States of America

Kunwar Shailubhai